View Older Stories View More Recent Stories

May 15, 2021 12:15PM Bristol Myers Squibb Presents Late-Breaking Phase 3 Data Demonstrating Health Status Benefits of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy at American College of Cardiology�
May 12, 2021 11:44AM Bristol Myers Squibb (BMY) Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
May 12, 2021 11:43AM Bristol Myers Squibb Presents New Research at ASCO and EHA 2021 Featuring Novel Approaches and Demonstrating Significant Progress to Improve Survival in Cancer and Blood Disorders
May 5, 2021 06:59AM Bristol Myers Squibb to Take Part in the 2021 Bank of America Securities Health Care Conference
May 3, 2021 09:11AM Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology’s 70th Annual Scientific Session
Apr 30, 2021 07:10AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review of Application for Opdivo as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Apr 30, 2021 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Apr 29, 2021 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2021
Apr 28, 2021 06:59AM Bristol Myers Squibb to Take Part in the 7th Annual Truist Life Sciences Summit
Apr 23, 2021 10:01AM Bristol-Myers Squibb (BMY) Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla
Apr 23, 2021 10:00AM Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Apr 23, 2021 06:53AM Bristol-Myers Squibb (BMY) Granted Positive CHMP Opinion for Onureg (azacitidine tablets; CC-486) as Maintenance Therapy for Adults with AML
Apr 23, 2021 06:51AM Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
Apr 23, 2021 06:47AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable MPM
Apr 23, 2021 06:45AM Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
Apr 16, 2021 01:12PM Bristol-Myers Squibb (BMY) Announces FDA Approval of Opdivo Combo for dvanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
Apr 16, 2021 01:10PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophage
Apr 14, 2021 04:20PM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo in Combination with Cabometyx as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Apr 14, 2021 04:16PM Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcino
Apr 13, 2021 02:00AM Evotec Launches 'BeLAB2122', Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
Apr 10, 2021 08:30AM Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Apr 8, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces Opdivo plus Chemotherapy and Opdivo plus Yervoy Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic ESCC
Apr 8, 2021 06:59AM Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metas
Apr 8, 2021 06:59AM  CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unr
Mar 30, 2021 06:59AM Bristol Myers Squibb to Host Virtual Investor Event to Discuss AAD VMX Highlights
Mar 29, 2021 06:59AM Bristol-Myers Squibb (BMY) Announces EMA Validates its Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Mar 29, 2021 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Muscle-Invasive Urothelial Carcinoma
Mar 29, 2021 06:29AM Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announces FDA Approval for Abecma for Relapsed or Refractory Multiple Myeloma
Mar 26, 2021 10:59PM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Mye
Mar 25, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces RELATIVITY-047 Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary
Mar 25, 2021 06:59AM Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets
Mar 19, 2021 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts its Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mar 19, 2021 06:59AM U.S. Food and Drug Administration (FDA) Accepts Bristol Myers Squibb’s Application for Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mar 11, 2021 06:59AM Bristol Myers Squibb to Report Results for First Quarter 2021 on April 29, 2021
Mar 2, 2021 06:59AM Bristol Myers Squibb to Participate in Barclays Virtual Global Healthcare Conference
Mar 1, 2021 04:16PM Bristol Myers Squibb Announces Dividend
Feb 26, 2021 06:26AM Bristol Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo in Combination with Cabometyx as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Feb 26, 2021 06:25AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Feb 25, 2021 01:00AM Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 RESULTS AND 2021 OUTLOOK
Feb 24, 2021 07:10AM Bristol Myers Squibb to Take Part in the Cowen Virtual 41st Annual Health Care Conference
Feb 24, 2021 06:59AM Bristol Myers Squibb Donates $11 Million to Advance Health Equity
Feb 23, 2021 09:00AM Bristol Myers Squibb and the American Music Therapy Association Team Up with Ben Platt and Sister-in-Law Courtney Platt to Launch MS in Harmony, a First-of-its-Kind Music Therapy Offering for People L
Feb 23, 2021 06:59AM Bristol Myers Squibb to Participate in Raymond James Virtual 42nd Annual Institutional Investors Conference
Feb 22, 2021 06:15PM Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of Certain of Their Senior Notes at “Make Whole” Prices
Feb 19, 2021 05:04PM Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion
Feb 18, 2021 09:29PM Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion
Feb 16, 2021 07:38AM Bristol Myers Squibb Canada (BMY), Acceleron Pharma (XLRN) Announce Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes
Feb 8, 2021 05:00PM OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the P
Feb 8, 2021 05:00PM Adjuvant Treatment with Opdivo (nivolumab) Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma i
Feb 8, 2021 12:30PM Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis
View More Recent Stories View Older Stories